CA2055594C - Percutaneous lymphography - Google Patents

Percutaneous lymphography Download PDF

Info

Publication number
CA2055594C
CA2055594C CA002055594A CA2055594A CA2055594C CA 2055594 C CA2055594 C CA 2055594C CA 002055594 A CA002055594 A CA 002055594A CA 2055594 A CA2055594 A CA 2055594A CA 2055594 C CA2055594 C CA 2055594C
Authority
CA
Canada
Prior art keywords
composition
contrast agent
particles
lymph nodes
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002055594A
Other languages
French (fr)
Other versions
CA2055594A1 (en
Inventor
Gerald L. Wolf
David M. Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alliance Pharmaceutical Corp
Original Assignee
Alliance Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharmaceutical Corp filed Critical Alliance Pharmaceutical Corp
Publication of CA2055594A1 publication Critical patent/CA2055594A1/en
Application granted granted Critical
Publication of CA2055594C publication Critical patent/CA2055594C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461Dispersions, colloids, emulsions or suspensions
    • A61K49/0471Perflubron, i.e. perfluoroctylbromide, C8F17Br emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • A61K49/126Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806Suspensions, emulsions, colloids, dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Injectable contrast agents of great clinical importance for lymphography are disclosed, characterized by non-water-soluble compositions with mean particle sizes between 10 nm and 500 or 1000 nm, which have selective distribution to lymph nodes upon percutaneous administration and can be imaged with millimeter resolution. Also disclosed are medicaments and uses of these compositions for performing percutaneous lymphography.

Description

PERCUTANEOUS I~YMPH'OGRAPHY
BACKGROUND OF THE INVENTION
The present invention relates to a method and compositions for imaging the lymph nodes in a mammal, including a human.
The spread of cancer to regional or distant lymph nodes alters prognosis and treatment. Thus, proper determination to of the stage of cancer in a patient requires evaluation of the lymph nodes along the lymphatic chain originating in the cancer. Imaging of lymph nodes i.s referred to herein as lymphography, and effective lymphography requires that the node be confidently identified, its size determined, and the intranodal anatomy or function be displayed. (The particular techniques disclosed herein may also appropriately be identified as "lymphadenography".) Imaging without direct infusion of contra;at agent into the lymph system is referred to as indirect l3nnphography.
2U Cancer cells that lodge and grow in lymph nodes may be identified by node enlargement, by altered sieving function, or by altered phagocytosis. Normal lymph nodes range in size from 1-15 mm and can be enlarged by hypertrophy or hyperplasia. Size as a criterion for cancer evaluations is poor unless the nodes are very large and the patient is known to have cancer. Some imaging devices have adequate spatial resolution for sizing lymph nodes, but lack the tissue discrimination to confidently distinguish lymph nodes from other biological structures with similar shapes.
These imaging modalities include x-ray, computed tomography, magnetic resonance imaging, and ultrasound. Radioisotope imaging does not have the required spatial resolution.
No contemporary imaging methodology can identify intranodal architecture without a contrast agent. A very few lymphatic channels in the body, usually those of the lower extremity, are large enough to~ isolate with a WO 90/14846 _2_ 2 ~ ~ ~ ~ ~ ~, PCT/US90/02984 surgical procedure and these can be injected with a contrast agent that is carried to their lymph nodes.
Thus, today's conventional technology for imaging lymph nodes utilizes direct infusion of contrast agent into a lymphatic channel. In this procedure, known as lymphangiography, the radiologist directly cannulates a large lymphatic vessel and injects it with a contrast agent, generally an oily iodinated medium that opacifies the sinusoids of a lymph node draining the injected lymphatic vessel. Unfortunately, lymphangiography is only in limited use and does not provide satisfactory results in general. The process requires surgical exposure and identification of the lymph vessel. This is technically difficult, but is an established procedure for lymphatic vessels of the feet. The injection and procedure time is two to three hours and filming is routinely done 24 hours later. Further, the solutions injected tend to image only a few leg, pelvic, and abdominal nodes. It is uncommon to obtain images of any lymph nodes in the chest and neck area, despite the major importance of imaging these nodes in the evaluation and management of lung and breast cancers.
In lymphangiography, the contrast medium seems to be lodged in lymph node sinuses by creating a viscous obstruction that cannot be cleared by hydrostatic forces within the sinusoid. If the lymph node is totally obstructed by cancer cells to begin with or partial obstruction has created collateral channels, the abnormal node will not be visualized and the dye may eventually reach the bloodstream where it will embolize the lungs with adverse effects upon respiratory gas exchange. Some of the major shortcomings of lymphangiography include the fact that direct dissection is required, which is expensive, requires skill and limits repeatability; further, it carries some morbidity. Moreover, the majority of lymphatic drainage beds and their associated lymph nodes are inaccessible; among them are common targets of cancer wo 90/ i asa6 2 ~ 5 5 5 ~ ~
such as the breast, the testis, the prostate, the cervix, the uterus, the kidneys, the liver, the intestines, and the lungs.
In addition to the danger associated with any prolonged procedure involving surgery, there are other dangers associated with lymphangiography that particularly relate to the contrast agent used in the procedure. If the agent chosen is water soluble or has a particle size that is too small, it will diffuse out of the lymphatic and may to also pass through the lymph node too easily. Currently, x-ray lymphangiography utilizes an emulsified ethiodized oil for direct injection into the lymphatic system. This material has a large particle size, is highly viscous, has marginal toxicity, and embolizes the lymph node. In instances where there is an undetected, direct lymphatic-venous connection, ethiodized oils could be directed into the systemic circulation, with harmful and potentially fatal results.
Indirect lymphography with :iodine formulations has usually been declared impossible (Mutzel, U.S. Patent 4,367,216; Hoey, U.S. Patent 4,225,725; Felder, et al., Swiss Patent 615,344) and iodine emulsions are also toxic (Mutzel). On the other hand, Japanese patent publication 42-25413 claimed development of an iodized vegetable fatty oil which was successful with intraperitoneal injection.
No details are provided to substantiate the claim; no toxicity data are provided for indirect lymphography nor have there been any reports of other positive experiments since the application date of September 28, 1365. Swiss Patent 615.344 discloses a crystal iodine formulation with a particle size of 1000 - 5000 nm. They claim that the lymphatic vessels and lymph nodes below the sternum can be regularly visualized after intraperitoneal injection. This is dubious - both as to success and the specific nodes claimed from this. injection route, particularly since there is no lymphatic flow downward from the sternum from the peritoneal cavity.

WO 90/14846 -4- ~ A ~p PCT/US90/02984 Other emulsions containing iodine have been prop~ .d for lymphography, but have not been adopted for that purpose. See, e.g., Swiss patent No. 615,344 and Japanese published application No. 25413/67. Toxicity problems are one major concern. Also, particle sizes of 1000 nanometers and above are unsuitable for indirect lymphography (with the possible exception of intraperitoneal injection. The peritoneum offers a huge surface and facilitated absorption of most drugs. The lymphatic vessels of the peritoneum are more permeable, especially those of the diaphragm where uptake is facilitated by respiratory motion.
Unfortunately, the lymph nodes accessible by this route are few and are of minimal clinical interest. Further, the intraperitoneal route places special limits on the toxicity of the lymphographic agent as direct access to the vascular space is facilitated by the thoracic duct.
Many researchers have experimented with radiolabeled materials as imaging agents for lymphography. There is a relatively rich literature on the development of radioactively tagged agents. Studies show lymphatic uptake and vascular exclusion is optimal for particles of about 40 nm. (See, e.g., Bergquist, et al. "Particle sizing and biokinetics of interstitial lymphoscintigraphic agents,"
Sem. Nucl. Med 13: 9-19, 1983.) These previous workers have also provided good information on animal models, pharmacokinetics and even human studies. (See also Ege, G.N., "Lymphoscintigraphy-techniques and applications in the management of breast carcinoma," Sem. Nucl. Med 13: 26-41, 1983). Unfortunately, radioactive isotopes trapped in lymph nodes provide poor spatial resolution and make it very difficult to determine details about the size of the nodes or the intranodal architecture.
Au198 and Ga67 have some avidity for lymph nodes and tumors, respectively. (See, e.g., Lymphatic Imaging:
Lymphography, Computed Tomography and Scintigraphy, 2nd ed., M. Close and S. Wallis, eds., Williams and Wilkins Co., Baltimore, 1985). The former is too energetic for WO 90/ 14846 ~ ~ ~ ~ ~ ~ ~ _ 5 _ PCT/ US90/02984 imaging and causes local tis~~8 c~ai~ne~ge. The latter is interesting, but is only useful for intravenous use and is not suitable for staging of lymph nodes. Recently, protein-specific reagents have been suggested for treatment purposes. (See, e.g., Weinstei.n, et al., "Monoclonal antibodies in the lymphatics: toward the diagnosis and therapy of metastases," Science 218: 1334-1337, 1982). At the moment, however, spatial resolution of isotope imaging devices precludes capitalizing on the selective distribution of tagged materials within lymph nodes.
In general, soluble and relatively small molecules such as albumin (<5nM) are either better absorbed from the interstitial space into blood than into lymph or they are poorly retained by lymph nodes so that they are ineffective for imaging intranodal architecture..
We c~nsider larger molecules t:o be particles and those up to 1 micron are called colloids while above 1 micron the particles are called suspensions. Microaggregated albumin fits in the former category while macroaggregated albumin is in the latter. Radiolabelled colloids have been of great interest for indirect lymphagraphy, despite the low spatial resolution of current cameras. However, the methods for measuring the size of candidate agents are poor. Bergquist et al (Sem. Nucl. Med. 1983;13:9) list 9 different techniques for measuring radiocolloid particle size. None is totally satisfactory and many colloid preparations also have a wide range of particle sizes. A
bimodal distribution in a particular preparation would invalidate a method that measures average size. Most preparations are better characterized by a complete distribution or histogram.
If the particles are rigid, then sizing is easier.
But if the particles are deformab:le, then sizing is more difficult. Most techniques measure size in vit~_-,~, but size may increase or decrease in vivo (Bergquist). Colloidal particles re usually coa'ced with a stabilizer prior to administration and are also coated (opsonized) in vivo.

WO 90/14846 -6- G ~ 5 ~ ~ PCT/US90/02984 The effective particle size includes the coat as well s the core, so this complicates the measurement. For imaging uses, the active contrast agent is usually limited to the core material.
The particles enter the lymphatics from the interstitium through gaps between lymphatic endothelial cells or by transcellular endo-exocytosis. The gaps change in calibre with physiologic or pathologic conditions.
Entry of the particle into the gap is believed to be a hit-or-miss affair and should be weakly related to particle size at dimensions less than the size of the gap. On average, smaller particles (10-50 nM) are more likely to enter than larger particles. However, larger particles usually carry more imageable material and are more effective per particle in altering the image intensity.
Thus, predicting imaging efficacy for a particular formulation is complicated. As particles approach 1000 nM, their uptake into lymphatics is so poor that they become ineffective. Very large particles in the interstitial space must be carried away by phagocytes or reduced in size by local processes.
Once particles reach the lymphatic space, a functional lymph node can very efficiently remove them, even if they are as large as a few thousand nanometers. This process requires particle coating, adhesion, and phagocytosis.
Cancer deposits in the lymph node destroy lymph node sinusoids and cancer cells have little or no phagocytic capacity. For both these reasons, cancerous regions accumulate particles poorly.
Virtually all particles--and the list is long and varied--selectively target normal parts of the node from the lymph in which they are carried. The influence of "sick phagocytes" upon sequestering particles in lymph nodes is unknown, but most processes causing hyperplasia or hypertrophy create functioning phagocytes and these nodes, though large, accumulate particles.

wo 9onasa6 2 0 5 ~ ~ ~ _.,_ _ _ rius9oio29sa Ethiodol--the standard lymphangiographic agent--is poorly phagocytosed and acts by sinusoidal blockade. This accounts for its spotty distribution creating a grainy appearance in normal nodes at moderate magnification. The germinal follicles in lymph nodes have few sinusoids and also few functioning macrophages. Both Ethiodol and particles will be sparsely accumulated in these regions.
A lymph node totally replaced by other cells, usually cancer, will receive no lymph but does continue to receive blood. Neither direct nor indirect lymphography will be effective in defining intranodal architecture in this circumstance. It may st.'~1 be possible to target such nodes with intravascular agents.
Clearly, despite the elegant compartmental models of Strand et al. (J. Nucl. Med. 1979;20:1038), most attempts to evaluate indirect lymphography agents rely heavily on actual animal experimentation. Mikheev (Atomic Energy Review 1976;14:1) writes, "As thE: measurement of colloid particle size presents great difficulties and the behavior of colloidal solutions in the body is only indirectly related to p~r_ticle size, it is more useful to control colloidal solutions by biologica:L studies in laboratory animals." On the other hand, it would be much easier to screen proposed agents in vitro were size distribution and imaging efficacy methods available and accurate. Such data would dramatically reduce the burd~an for animal studies and would enable the investigator to identify anomalous responses that might aid in further understanding of this complex biological process.
3o There is at least one reported attempt at indirect lymphography through injection of radiopaque perfluorocarbons subcutaneously into the peritoneal or pleural spaces or into the lung parenchyma. However, animal tests involving injection of both neat and emi-'sified radiopaque perfluoroca:rbon failed to produce clinically useful information. D. Long, et al., Radiology 133: 71-76 (1979). Instead, rac~iopacification of lymph nodes with emulsions was sporadic and was observed only n one animal eight months following administration of the perfluorocarbon. This outcome is too inconstant and too delayed for clinical applications.
Other attempts to perform direct or indirect lymphography have utilized dimers of iodinated water soluble agents. The dimer increases molecular size, and reduces diffusion from the lymphatic to some degree;
however, these small soluble agents appear to provide only transient opacification of the lymph node.
Accordingly, there is a need for a lymphographic technique and contrast agent that permits imaging of lymph nodes in any desired area of the body within a reasonable time period. Such imaging would identify location, size, and internal architecture of regional lymph nodes of interest and would permit differentiation between lymph node enlargement due to hypertrophy and hyperplasia of normal node constituents, on the one hand, and neoplasia, on the other hand.
Moreover, there is a need for a lymphographic procedure that minimizes procedure time and patient discomfort, while reducing the dangers of the procedure.
These and other objectives are met by the present invention.
SUMMARY OF THE INVENTION
The present invention utilizes contrast agents that have particular characteristics that facilitate their uptake into lymphatics and retention in the regional lymph nodes. Although a wide variety of contrast agents can be used, we have discovered that they must have one common parameter: appropriate particle size.
Lymph nodes process material delivered by the afferent lymphatics; the material delivered is fluid, particulates, and cells. The lymph node removes material by sieving or phagocytosis. Noncellular material enters the lymphatics from the interstitial fluid through gaps between the lymphatic endothelial cells, and also by endocytosis.

WO 90/14846 ~ ~ ~ ~ ~ ~ ~ -9- _- PCT/US90/02984 Because the gaps are not fixed in an anatomic sense, any given gap can intermittently open and close. The buildup of interstitial fluid or tissue motion tends to open the gaps wider or more frequently, increasing the amount and size of material that enters.
Fluids and particles up to 5 nm in diameter within the interstitial space are not preferentially taken up by the lymphatic system, but are instead absorbed more rapidly by the blood circulation. On the other hand, particles larger than 5 nm are poorly absorbed by blood capillaries. When the particle size reaches 900 nm, 1000 nm, and greater, particles are expected to only poorly penetrate into the lymphatic system. Particles between 5 or 10 nm and 500 or 900 nm, then, are those we have identified as most likely to be preferentially taken up by the lymphatic system and to be retained in the lymph nodes.
In brief, then, the present invention is directed to contrast agents suitable for imaging by one or more imaging techniques, which agents are in particulate or colloidal form and are adapted to be preferentially taken up by the lymphatic system upon percutaneous or interstitial administration. These contrast agents can be radiopaque materials, MRI imaging agents, ultrasound imaging agents, and any other contrast agent suitable for a device that images an animal body. They are preferably nontoxic, and should have a mean particle size between 5 or 10 nm, as a minimum, and 500 or 900 nm, as a maximum. Of course, in any given particulate system, particle sizes usually form a distribution. Thus, it is preferred that the mean particle sizes fall within the range of 5 to 900 nm, preferably within the range of 10 to 500 or 800 nm. Alternatively, it is desired that at least 80 percent of the particles, by volume, fall into the range of 5 or 10 nm to 800 or 900 nm.
In preferred embodiments, the average or mean particle size is at least 20 nm and may also advantageously be less than 500 nm. Formulations in which the mean particle size is no more than 300 or even 250 nm are also contemplated, as are formurations with a mean particle size of less than 150 Also, we believe there are particular advantages to formulations in which at least 20~ of the particles, by volume, are less than 300 nm or 200 nm.
The particular type of particle can be selected from a wide range of possibilities. Polymers of appropriate size can be used. Colloids are also within the scope of the present invention, as are emulsions with appropriate particle size.
In one embodiment of the present invention, the mean size of the particles in the emulsion is less than 250 nm.
The emulsion droplet is preferably stabilized with an emulsification agent, such as a surfactant. Particularly advantageous are phospholipid surfactants, which inherently may affect the biocompatibility, uptake by the lymphatics, and overall rheological properties. The appropriate size may also be obtained with small liposomes that carry contrast media. Finally, the viscosity of the formulation ~is believed to be significant. Our data suggest that large particle sizes and viscous compositions do not readily and rapidly enter the lymphatic system. Thus, we prefer compositions having a viscosity measured at 25°C at a shear rate of 11.5 sec-1 of 50 cps or less, preferably not more than 35 or 40 cps, and most preferably less than 20 or 25 cps. We have had good results with emulsions having viscosities of under 10 cps and particularly under 5 cps.
In additional variations, preferred compositions may also comprise a non-radioactive contrast agent in particulate or colloidal form, wherein the mean particle size is 10 to 900 nm in diameter, the composition being adapted to localize in lymphatic system tissue afferent to a site where the contrast agent has been interstitially administered, for performing percutaneous lymphography to allow imaging of the lymphatic system tissue in which the contrast agent has localized. Additional embodiments disclose compositions wherein the particles comprise an 2 0 5 5 5 ~ -11- ~'/US90/02984 ' imageable moiety and an appropriately sized particulate carrier incorporating the imageable moiety.
A pharmaceutical composition for use as a contrast agent for interstitial administration in a mammal for indirect lymphography, characterized by an imageable non radioactive contrast agent in particulate or colloidal form having a mean particle size between 5 nanometers and 900 nanometers, in a pharmaceutically acceptable carrier suitable for injection, and adapted to localize in lymphatic system tissue afferent to the site of administration of the composition, is also disclosed. In another embodiment, the composition may further comprise packaging material associated with the particulate material carrying indicia reflective of governmental approval for interstitial administration of the particulate material as a contrast agent for indirect lymphography. In yet another embodiment, -~t least 20% of the particles are 200 nanometers in diameter or less, while, in additional variations, the particles are superparamagnetic or ferromagnetic, or comprise an insoluble metal colloid, a lipid-soluble iodinated compound or an imageable fluorocarbon. The invention further includes use of disclosed agents wherein the contrast agent is a brominated perfluorocarbon, such as a mono-brominated perfluorocarbon. In another embodiment, the contrast agent is perfluo~ooctylbromide. Additional embodiments suggest that the contrast agent is a mono- , di-, or tri-iodinated perfluorocarbon. In yet another variation, the mean size of the particles is less than 300 nm.
Use of an imageable particulate material having a mean particle size between 5 nanometers and 900 nanometers in the preparation of a medicament for use as a contrast agent for interstitial administration to perform indirect lymphography is also disclosed herein. Other examples of uses are disclosed, e.g., wherein t:.he site of interstitial administration comprises a hand, foot, or limb, to allow imaging of axillary, popliteal, or lingual nodes.
Alternatively, the site of interstitial administration may t -12- ~ ~/US90/02984 be the chest or face, in order to image the axillary r cervical nodes.
For x-ray and computed tomography imaging, the contrast agent should have an adequate electron density to render it visible with these techniques. Suitable electron density is achieved, e.g., in compounds with bromine or iodine moieties, and in materials comprising or including radiopaque metal atoms.
For MRI, one looks to materials that have adequate nuclear or relaxation properties for imaging that are different from the corresponding properties of the tissue being imaged. Either an imageable nucleus (such as 19F) or a ferromagnetic or paramagnetic material can be used with appropriate MRI equipment.
Ultrasound and x-ray imaging, including the use of digital subtraction techniques, may also be utilized according to another embodiment of the present invention.
Ultrasound contrast agents can be selected on the basis of density or acoustical properties.
In one embodiment of the invention, there is disclosed a method for performing indirect lymphography, comprising the steps of interstitially administering a non-radioactive contrast agent in particulate or colloidal form to a mammal, the agent having a mean particle size from about 5 to about 900 manometers in diameter, permitting the contrast agent to localize in lymphatic system tissue afferent to the injection site, and imaging the lymphatic system tissue in which the contrast agent has localized within about 1 month of the administration.
The present invention also discloses methods for preparing emulsions, and further discloses methods for concentrating such emulsions, including dialysis, ultrafiltration, and reverse osmosis.
Preferred contrast agents include emulsions of perfluorooctylbromide ("PFOB") and other radiopaque perfluorocarbons, imageable fluorocarbon compounds, perfluoroalkylated ethers and perfluoroalkylated ether WO 90/14846 _ _ bromides, as well as colloids or particles of gold, iron, chromium, gadolinium, yttrium, zirconium, hafnium, tin or antimony as oxides, phosphates, sulfides, or silicates.
Paramagnetic, superparamagnetic, and ferromagnetic particles of chromium, gadolinium, iron, manganese, ferrites, and magnetite are also contemplated, as are imageable compounds linked to or incorporated with dextran, albumin, latex, polystyrene, or other particulate materials of appropriate size.
l0 Other compounds are also 'contemplated by the present invention, including magnetic: polymer particles, organomagnetic particles, microspheres, and biologically active magnetic particles such as those discussed in U.S.
Patent No. 4,795,698 to Owen, and in the patent references cited therein. The particles, colloids, or emulsions may have stabilizers to assure size and dispersion in vivo.
Moreover, the particles may be coated with various materials, such as the polysaccharide-coated iron oxide particles described in U.S. Patent No. 4,452,773 to Molday.
The present invention further contemplates the use of hydrophobic particles, insoluble metal colloids, lipid-soluble iodinated compounds, or other iodinated compounds, including those in which the iodine atom is contained within the perfluorocarbon molecule. In one particularly preferred embodiment of the invention, however, the particulate is noniodinated. Although some embodiments of the invention may utilize iodinated fluorocarbons, it is preferred that non-fluorocarbon iodine compounds, such as iodinated oils and crystals, are excluded.
The method of the present invention involves interstitial injection (or other interstitial administration) of the contrast agent in the vicinity of the lymph nodes to be imaged. Interstitial injection includes injection subcutaneously (under or in the skin) and intraparenchymal injection (into an organ), but does not include injection into a body cavity, such as intraperitoneal injection. In the case of cancer patients, -14' 2 the involvement of lymph nodes is preferably evaluated =r injecting the contrast agent in proximity to the cancer.
The contrast material is then taken up by the lymphatic system, and tends to localize in lymph nodes afferent to the uptake site. Thus, the contrast agent follows the same route as a metastatic tumor cell would be likely to follow within the lymphatic system.
After an appropriate waiting period, usually a few hours to a few days, the lymph nodes are imaged and the size and intranodal anatomy of the nodes are evaluated in order to determine their location and normality, including possible cancerous involvement. A waiting period of between 3 days and one month is preferred, and between 4 days and 15 days is particularly preferred.
The present invention additionally discloses a process for the preparation of a fluorocarbon emulsion, the process comprising forming an aqueous emulsion having an aqueous phase and having a fluorocarbon phase, and removing at least some of the aqueous phase to concentrate the emulsion by dialysis, ultrafiltration or reverse osmosis. In another variation of the process, the fluorocarbon phase has a mean particle size less than 150 manometers. In yet another variation, the concentrating step comprises dialysis, ultrafiltration, or reverse osmosis. Moreover, at least 20 volume percent of the fluorocarbon phase may have a particle size less than 300 manometers, in another embodiment.
DETAILED DESCRIPTION OF THE INVENTION
There are a number of particulate contrast materials that can be used in the practice of the present invention.
1. Fluorocarbon Emulsion Contrast Accents One particularly preferred category of contrast materials includes radiopaque fluorocarbons in the form of emulsions. These materials are substantially nontoxic, and can be eliminated quite readily from the body. We have prepared perfluorooctylbromide ("PFOB") emulsions with a range of particle sizes to be injected subcutaneously for WO 90/ 14846 Z ~ ~ ~ ~ g ~ _ _ 15 _ ""'' ~"S90/02984 imaging lymph nodes. Through a series of experiments it was determined that a mean particle size range of 10 to 900 nanometers (nun) was particularly suitable. Emulsions with these properties were prepared with PFOB and egg yolk phospholipid in an aqueous vehicle. (Of course, other concentrations may also be used.) Emulsification was accomplished as reported in Published European Applications Nos. 231,070 and 307,087, and U.S. Patent No. 4,865,836.
These emulsions are often more dilute than those used for liver-spleen imaging but also have much smaller target tissue mass. The viscosity of the: emulsion is preferably less than 50 cps at 25°C measured at a shear rate of 11.5 sec-1. If necessary, the volume of the emulsion used may be decreased by concentrating the emulsion via physical methods, such as centrifugation. Concentration of the emulsion may also be achieved using reverse osmosis, dialysis, or other methods, including ultrafiltration, microfiltration, and ultracentrifug~ation. In addition to PFOB, other radiopaque fluorocarbons can be utilized, such as nontoxic fluorocarbon iodides, and the perfluorocarbon bromides disclosed, for example, in U.S. Patent Nos.
3,818,229, 3,975,512, and 4,073,879. The fluorocarbon iodides may be mono-, di-, or tri-iodinated perfluorocarbons. In the fluorocarbon embodiments of the present invention, the fluorocarbon is preferably in the form of an emulsion, with a mean particle size of from 5 to 900 nm, and preferably less than 500 nm. Most preferably, a mean particle size of less than 300 nm is utilized.
The present invention includes radiopaque fluorocarbon emulsions suitable for percutaneous lymphography, comprising an aqueous phase and a fluorocarbon phase, wherein the fluorocarbon phase comprises particles having a mean particle size as set forth above. PFOB emulsions are preferred. Moreover, the most preferred fluorocarbon emulsions are highly concentrated, and have a fluorocarbon concentration of at least 30%, preferably 35% or 40%, and more preferably at least 50% or 55,s fluorocarbon, w/v. At the upper end, the emulsions preferably have no more t' n 125% fluorocarbon, w/v. While emulsions can be prepared in any suitable way, the preferred method involved passing a mixture of water, fluorocarbon, surfactant, and any desired excipients through a high pressure mechanical emulsifying apparatus, in which the mixture is subjected to high shear conditions or conditions of high mechanical stress. Such emulsifiers typically operate at pressures of 2000 psi to 25,000 psi and direct the mixture at high speed along a nonlinear path to generate the emulsion. Usually several passes through the apparatus can be used to generate a uniform and stable emulsion. Suitable emulsification devices are commercially available from Microfluidics Corporation (Newton, Mass.), model number M-110. Also appropriate for use is the Ranie Homogenizer 12-51 from Albertslund (Copenhagen, Denmark), as well as other high pressure valve homogenizers.
In order to control the particle size and rheological properties, we have found that the initial concentration of fluorocarbon phase is important. Optimal properties seem to be generated with fluorocarbon concentrations between 20% and 40%, w/v, and 30% emulsions have provided good results in our studies, forming emulsions with mean particle sizes at or below 500 nm and viscosity less than 50 cps at a shear rate of 11.5 sec-1 measured at 25°C. After formation of the emulsion, it is advantageous to sterilize it in a steam autoclave. Suitable sterilization parameters include sterilization at approximately 110°C for 15 minutes. Either before or after sterilization, the emulsion can be concentrated in order to minimize the volume of material administered to the patient.
Concentration can be accomplished by dialysis, ultraf filtration, reverse osmosis, and the like. In particular, DDS microfiltration (nanofiltration) membrane GRM1.OPP (Niro Atomizer Food & Dairy Inc., Hudson, WI), comprised of polysulphone and having a molecular weight cutoff of 1 micron (~) -- 1~ being equivalent to a WO 90/14846 2 0 5 5 ~ 9 ~ -17- ~'~T/US90/02984 molecular weight of 10 million -- may be utilized: also effective is DDS microfiltration membrane GRM0.2PP, with a molecular weight cutoff of 0.2~c, or GRMO.1PP, with a molecular weight cutoff of 0.1~. Alternatively, if ultraf filtration is used, the membrane which is most effective is DDS polysulphone ultrafiltration membrane CR10PP, with a molecular weight cutoff of 500,000 (0.050 .
All of the aforementioned membranes are usable at temperatures ranging from 0°C to 75°C and at pH ranging from 1-13. If ultrafiltration is the process of choice, approximately < 100 pounds per square inch (psi) is appropriate. If nanofiltration is utilized, 100 - 400 psi may be used, whereas approximately 600 psi is appropriate for reverse osmosis.
2. Other Radiopacfue Contrast Agents In addition to radiopaque fluorocarbon emulsions, other radiopaque materials can be used in the practice of the present invention, so long as they are in the form of injec~_able materials having the required particle size characteristics, appropriate fluidity, and adequate safety.
Iodinated materials have long been used as contrast agents in computed tomography and x-ray procedures. There are a number of water-insoluble organic compounds, for example, that have been iodinated in the prior art.
Ethiodated oils, for example, are presently used in lymphangiography. U.S. Patent No. 4,404,182 discloses ethiodized oil-based contrast agents, including emulsions thereof. Although the emulsions in that patent had particle sizes of 2-3 microns, emulsification techniques similar to those described above could be used to form emulsions with suitably small particle sizes for use in the present invention.
Iodinated fatty acid esters of poppyseed oil and other oils are currently in use for lymphangiography. These materials can be used in the practice of the present invention when formulated into emulsions having the requisite particle size. Moreover, other iodinated fa*'~v materials or corresponding brominated materials can similarly be used in practice of the present invention.
Some toxicity has been reported for these materials;
accordingly, less toxic agents are preferred. However, use of these already-approved materials in the practice of percutaneous lymphography is contemplated as within the scope of the present invention.
In addition to iodinated or brominated materials, a number of other electron-dense materials can be used in the present invention. The electron density can be provided by non-radioactive elements or compounds such as gold or iron, chromium, gadolinium, yttrium, zirconium, hafnium, tin or antimony as oxides, phosphates, sulfides, or silicates, as well as other nonradioactive metals. The foregoing can advantageously be utilized in the form of colloids or particles of appropriate size.
Alternatively, other agents may be used to form particles having the requisite size from the foregoing materials. It is well known that dextran, albumin, latex, polystyrene, and other proteins, synthetic polymers, and the like can be obtained in particles having the size characteristics set forth above. Liposomes can also be formed using conventional techniques that have the necessary particle sizes. While these particles per se are generally unsuitable for imaging use, they can be used in the present invention in combination with imageable materials. Thus, for example, submicron particles of radiodense materials can be linked to, encapsulated by, or physically incorporated into these particulate compounds using known methods. Before use, they are preferably suspended in a suitable injectable carrier, such as phosphate buffered saline, optionally in combination with of any of the well-known physiologically acceptable surfactants. Preservatives and antimicrobials may also be used in conventional concentrations.

3. MRI Imaging Agents w - -- -.
While the foregoing radiodense materials can be used for computed tomograprw and x-ray imaging of the lymphatic system, MRI contrast agents are also desirable in the practice of the present invention. MRI has some technical advantages over conventional radiology and radiolabeling in that lymph nodes have inherent differences in their proton spin relaxation compared to that of fatty tissue; however, there is little tissue contrast within nodes, and thus node enlargement is the only available criterion of abnormality, when MRI is used.
The terms "T1" and "T2" are terms of art that refer generally to the relaxation time of proton spins. The proton spin density and relaxation times are essentially what proton MRI detects. Since fatty tissue has short T1 and long T2 relative to other tissues, the superparamagnetic or ferromagnetic class of agents that selectively shorten T2 is favored. A superparamagnetic particle of optimum size may be administered subcutaneously or intraparenchymally to contrast any desired chain of lymph nodes. One may also coat such particles with monoclonal antibody to provide a degree of cell specificity within the lymph node or other tissue of interest. A
dextran coating may also be used to reduce aggregation.
Although inherent tissue contrast is a major strength of MRI, some tissue pairs lack inherent contrast and both tissue specificity and functional characterization are suboptimum. Contrast agents thus have the potential to improve MRI for some clinical applications. In particular, they can be used to advantage in imaging of the lymphatic system in accordance with the present invention.
There are two major classes of contrast agents:
paramagnetic and superparamagnetic. Paramagnetic agents have unpaired electron spins that: facilitate relaxation of nuclei, usually water protons, that can closely approach them (within 1 nm). These agents decrease both T1 and T2, are effective in ~M concentrations, and can be incorporated WO 90/ 14f _ 2 0 _ ~ PCT/US90/02984 in ~chelates with favorable biodistribution and toxic-''.y profiles. Schering's patented product, GdDTPA (gadolinium diethylenetriaminepentaacetic acid), is an outstanding example of several commercially available such agents. To be useful for lymphography, this class of agents must be incorporated into macromolecules to avoid uptake by the systemic circulation. Combination with albumin, other biological molecules of appropriate size, latex, dextran, polystyrene or other nontoxic natural or synthetic polymer, l0 or encapsulation in liposomes, can be accomplished as set forth above.
Although this represents one substantial aspect of the present invention, there are at least two reasons for preferring the superparamagnetic or ferromagnetic class.
First, for detecting the size of lymph nodes, the fat surrounding the node provides a valuable contrast to the node itself. The presence of paramagnetics in a lymph node would principally reduce T1 and would make lymph nodes more isointense with surrounding fat, and thus more difficult to identify. This could be overcome with subtraction techniques, but lymph node uptake from interstitial depots occurs over 2-72 hours and this makes precise repositioning (for subtraction) of structures measuring less than 2 cm somewhat difficult. Second, clusters of unpaired spins that create superparamagnetic or ferromagnetic fields within the magnet are much more potent and selectively decrease T2. As lymph nodes already have shorter T2 than fat, a superparamagnetic agent would increase tissue contrast against fat.
Of equal importance is the fact that the physical size of agents that are required for lymph node targeting is virtually in the same size domain as many suitable superparamagnetic agents. This is true of particles of superparamagnetic ferrites and magnetites. Finally, the superparamagnetics_ are effective at all fields and with nearly all pulsing sequences, thus facilitating their ultimate use in clinical circumstances.

WO 90/14846 """'/US90/02984 205~~-2i-Happily, many of the contrast: agents discussed herein can be used in multimodal imaging'. For example, the MRI
contrast agents are usually also electron dense materials, and thus can be used for both CT or x-ray imaging as well as MRI. PFOB emulsions are also quite useful for MRI.
Moreover, many of the foregoing materials, such as fluorocarbon emulsions, magnetite suspensions, and the like can be used as ultrasound contrast materials as well.
Among potential imaging agents, our data indicate that the following contrast agents, among others, would be effective:
1. For CT and Digital x-ray: PFOB emulsions;
emulsions of ethiodized oils or other iodinated or halogenated lipophilic materials:
2. For ultrasound: PFOB emulsion, magnetite suspensions, other heavy or air trapping products.
3. For MRI: PFOB emulsion,, metal dioxide colloids such as zirconium dioxide colloid or Gd203 colloid, paramagnetic macromolecules, supex-magnetic or ferromagnetic particles, other similar emulsions, and small liposomes with entrapped materials.
4. Method for Performinct Percutaneous Lymphography The methods of the present invention are straightforward. In brief, an imageable amount of a suitable contrast agent prepared as set forth above or in the Examples that follow is injected interstitially (subcutaneously or intraparenchymally) into the animal to be imaged. After sufficient time has elapsed to permit localization of the agent into the lymphatic system of the animal, a conventional imaging stE-p is performed.
Because of the preferential uptake of the contrast agent into the lymphatic system, relatively small amounts of contrast agent are needed. For example, to image the lymph nodes of the neck in a human using CT and ultrasound, approximately 1-5 cc of 30~ w/v PFOB emulsion is injected subcutaneously in the vicinity oi: the lymphatic tributaries draining to the target node, preferably in front of ~r behind the ear, or at the site of a known tum~r.
Similarly, approximately 1-2 cc of Gd203 microcolloid suspended in phosphate buffered saline at a concentration of 0.1 - 0.5 M can be used for MR imaging of the same area.
In both cases, the amount of time between injection and imaging is between approximately 1/2 hour and 72 hours, preferably between 24 and 48 hours.
Similarly detectable amounts of other contrast agents will be readily determinable to those of skill in the art by reference to the foregoing information. Moreover, a simple dilutional and time study in rabbits of the type reported in the Examples, can be used to readily determine suitable amounts for other contrast agents and/or imaging methodologies.
The present invention is particularly suitable for imaging lymph nodes for detection of neoplasms or other disease. We have found that there is some variability in the uptake of these materials by region. In the rabbit, for example, greatest uptake is from forelimb to axillary node, followed in order by: hindlimb to popliteal node, cheek to cervical node, chest to axillary node, and thigh to inguinal node.
In humans, then, injection into the hand or arm is used to image the axillary nodes, injection into the foot or leg is used to image the popliteal node, injection into the cheek or face is used to image the cervical node, injection into the chest is used to image the axillary node, and injection into the thigh is used to image the inguinal node.
5, Pre aration of Medicaments for Percutaneous Lymphoctraphv The present invention also includes the use of the particulate materials described herein in the preparation of a medicament for use in performing indirect or percutaneous lymphography on the human or other mammalian 2 0 5 5 5 9 4 -2 3 - ~"/US90/02984 body. The medicament may be prepared, for example, by suspending the imaging particles in a pharmaceutically acceptable injectable carrier of conventional composition.
The carrier, in the case of an emulsion, is the aqueous phase of the emulsion. Suitable osmotic and buffering agents may be used in the formulation, as is conventional in the pharmaceutical arts. The medicament is preferably packaged with directions or instructions indicating that it is to be used for indirect lymphography by interstitial administration, and imaged within one month or less. Also, the medicament may be packaged in a container accompanied with an indication that the formulation has received governmental regulatory approval for use in humans for indirect lymphography. Such approval, for example, is obtained from the U.S. Food and Drug Administration for medicaments sold in the United States.
Particular embodiments of the present invention can be readily understood by reference to the following Examples, which are intended to be representative and not limiting.

Example I
Pre aration and Concentration of Perfluorocarbon Emulsio~.
An emulsion having suitable particle size and theological properties was prepared by forming a mixture comprising:
Ingredient Percent (w/vL
Perfluorooctylbromide 30 ggg yolk phospholipid 6 Mannitol, USP 0.4 Sodium chloride 0.5 Disodium calcium edetate 0.015 d-«-tocopherol acetate 0.05 Buffered at pH 8.2 prior to sterilization This mixture was passed 5 times through a high pressure mechanical emulsifier (Model M-110, Microfluidics Corporation, Newton, Mass.) at a pressure of 15,000 psi.
The resulting emulsion was terminally sterilized at 121°C
for 15 minutes. The sterilized emulsion had a median particle size diameter of 190 nm with 53% of the PFOB
particles less than 200 nm and 3.40 of the PFOB particles greater than 500 nm. The viscosity of this preparation at 25°C was 3.4 cps at a shear rate of 11.5 sec-1 and 3.0 cps at a shear rate of 46 sec-1.
Using the same formulation, the particle size distribution was modified by varying the number of passes through the emulsification apparatus, to give the following emulsions A-D:
Volume Fraction.
Batch Mean Diameter nm <200 nm >500 nm 1 200 ~ 90 61.4 2.0 2 210 ~ 100 54.6 2.0 3 180 ~ 80 73.0 0.5 4 310 ~ 210 40.0 36.0 _25_ . ~.., v.~w. v~yo., These emulsions were used in generating the data in Example III, below.
The emulsions of this example can be concentrated, if desired, to form higher concentration emulsions.
_. 5 Concentration is accomplished via utilizing dialysis, ultrafiltration, nanofiltration, reverse osmosis, and the ' like. For example, one embodiment uses DDS microfiltration (nanofiltration) membrane GRM1.OPP (Niro Atomizer Food &
Dairy Inc., Hudson, WI), comprised af_.polysulphone and having a molecular weight cutoff of 1 micron (~), although DDS microfiltration membrane GRM0.2PP, with a molecular weight cutoff, of 0.2~, or GRMO.1PP, with a molecular~weight cutoff of 0.1~, may also be used effectively. Another preferred, embodiment employs ultrafiltration as the concentrating method.' The membrane which is most effective in such applications' is DDS polysulphone ultrafiltration membrane CR10PP, with a molecular weight cutoff of 500,000 (0.050 . All of the aforementioned membranes are usable at temperatures ranging from 0'C to 75'C and' at pH ranging from 1-13. If ultrafiltration is the process of choice, approximately < 100 pounds per square inch (psi) is appropriate. If nanofiltration is utilized, 100 - 400 psi may be used, whereas approximately 600 psi is appropriate for reverse osmosis.
Alternatively, a higher concentration eanulsion can be prepared ~b initio using the procedure of this Example while increasing the PFOB concentration. Decreases in phospholipid emulsifier may be desirable at higher concentrations of PFOB (e.g., 4.5% phospholipid for a 75%
PFOB emulsion).
Examp a II
Preparation of MRI Contrast Acxents Magnetite spheres were obtained as*Biomag M4125 from Advanced Magnetics, Inc. (Boston, MA) having a mean particle size of,500 nm. (Another commercial source for magnetite particles is*Immunicon (Huntington Valley, PA).) Alternatively, particulates are prepared via the TRADE MARK

WO 90/14846 ~ ~ ~ ~ ~ ~p~'/US90/02984 procedures described in Elmore, W. C., Phys. Rev. 54: 3~'~-310 (1939) or McNab, et al., J. Appl. Physics 39: 5703-511 (1968). These particles are studied uncoated. In addition, we prepared particles coated with dextran and particles coated with serum albumin to reduce aggregation and to facilitate lymphatic uptake. Coated particles are prepared generally as set forth by Molday, et al., J. Immunol. Meth.
52: 353-367 (1982).
GdDTPA was coupled to 60,000 mw dextran using the bis anhydride of DTPA via the procedures described in Hnatowich and Siegel, Science 220: 613-615 (1983).
Example II7:
P_ercutaneous Lymphography of t:he Rabbit with PFOB
A. Protocol 1 Adult male NZW rabbits each weighing approximately 2-2.5 kg were given subcutaneous PFOB emulsion at various time intervals using the 30~ w/v PFOB emulsion of Example 1 (first formulation) and a 0.6 gm/injection site dose. The following table represents the mean and standard deviation values of PFOB concentration (mg PFOB/gm tissue) at these various time intervals:
Time Lymph Mean Std. Dev. No.
Interval Node Samples 24 hrs Cervicall 9.20 4.74 11 Axillary2 27.35 12.57 11 Inguinal3 6.20 6.63 11 Popliteal4 16.57 4.51 11 48 hrs Cervical 17.72 10.46 3 Axillary 39.46 27..16 3 Inguinal 6.09 6..47 3 Popliteal 27.73 9..35 3 72 hrs Cervical 18.69 14.73 Axillary 75.34 23.39 9 Inguinal 6.82 9~19 Popliteal 39.09 14.89 9 1 week Cervical 19.90 14.51 Axillary 86.78 37.68 12 WO 90/ 14846 ~ n ~ ~ ~ -2 7 pCT/US90/02984 ~ ~ _ Inguinal 3.59 4.77 11 Popliteal 47.28 19.60 12 2 weeks Cervical. 9.34 7.74 6 Axillary 55.39 19.88 6 Inguinal 5.03 5.24 5 Popliteal 27.32 10.82 6 1 month Cervical 11.82 5.53 8 Axillary 46.86 6.79 8 Inguinal 0.64 0.2T 4 Popliteal 20.85 3.42 8 1 Injection site: cheek 2 InjE:ction site: forepaw 3 Injection site: thigh 4 Injection site: hindpaw B. Protocol 2 To demonstrate the efficacy of indirect lymphography using PFOB; four separate 30% emulsions were prepared and administered to rabbits at a do:ae of 0.3 gm into each forepaw. (These are emulsions A--D in Example 1.) Each rabbit was imaged by CT using i~hin section, contiguous slice techniques to identify and quantitate radiopacity of the axillary node. Two different methods of measuring node intensity showed excellent correlation (CT console expressed in Hounsfield units, Optimal software on a Zenith workstation expressed in arbitrary units, R=0.99).
Each rabbit was imaged only once and then sacrificed.
Axillary nodes were removed and PFOB concentration 0 determined by Gas Chromatography. The correlation between peak CT intensity of enhanced node and lymph node PFOB
content was significant (R=0.82; for Hounsfield units, R=0.79 for Optimal units). The. imaging intervals after forepaw injection were 3 days ('n=20): 7 days (n+12): 10 days (n=7): and 12 days (n=13). At all four time periods, each 30% emulsion showed consistent and dense opacification of the target node. Peak opacification was seen at 10 days, but all time periods were judged to identify normal intranodal architecture with sufficient enhancement for clinical diagnosis.

_2s_~1 Blood chemistry, histology of lymph nodes ~d injection sites, and clinical follow-up of the rabbits ror weeks and monkeys for months revealed no evidence of local or systemic toxicity.
All of these emulsions demonstrated efficacy in indirect lymphography.
C. Protocol 3 Percutaneous lymphography with 30~ PFOB emulsion was l0 performed in six (6) Macaques weighing 6 - 25 lbs. each.
1.0 cc of the emulsion was injected into the toe web spaces of the left foot. After 3, 7, and 17 days, the left inguinal node was easily visualized on thin-slice CT images in all six primates. These animals were followed clinically for more than 1 year without any untoward effects evident at the injection site or in their general health.
Example VI
To demonstrate the poor results of lymph node opacification with larger particles, a colloidal suspension of 0.2 Gd203 with an average particle size of 932 nM was injected subcutaneously in cheek and sternum of rabbits.
These rabbits were serially imaged over 30 - 60 days. The injection sites were densely opacified on CT scans but no lymph node opacification was obtained in any rabbit.
Dilution and coating of the radiopaque colloidal particles with dextran (two additional injections) did not lead to detectable absorption from the injection site or lymph node opacification.
Example V
MR Ima inct with Gadolinium Contrast Agent GdDTPA coupled to 60,000 mw dextran (from Example II) was administered subcutaneously to twenty rats along with India ink to visually mark the lymph nodes. The rats were sacrificed twenty-four hours later and their lymph nodes WO 90/14846 -29- ' PCT/US90/02984 showed the characteristic high field peak of Gd-macromolecules. Rat lymph nodes are too small to image with our Signa systems.
Example V
MR Imaging with Su~erparamagmetic Maanetite Particles Magnetite disproportionately decreases T2 relaxation of adjacent protons. Initially, ether-anesthetized rats received 0.1 ml (1 mg iron) of :magnetite spheres (from Example II) in each foot pad. 12 -16 rats in each group were sacrificed and their lymph nodes were examined with in vitro relaxation time measurements. The T2 of their lymph nodes were as follows:
Control 3 hrs 6 hrs, 12 hrs 24 hrs T2 (mean) 65 61 58 39 29 The relatively slow uptake suggested that the particles could be clumping and/or that inactivity following the anesthesia was delaying lymphatic absorption.
For this reason, 1~ dextran was added to reduce aggregation and other rats were exercised for 15 minutes by forced swimming and sacrificed three hours later. The results are shown below.
Magnetite Magnetite Magnetite Magnetite without without with + c~ -=~xtran dextran + swim dextran + swwim T2 (mean) 48 43 33 22 Although the invention has been described in the context of particular embodiments, it is intended that the scope of coverage of the patent mot be limited to those particular embodiments, but be determined by reference to the following claims.

Claims (22)

WHAT IS CLAIMED IS:
1. A composition comprising a diagnostically effective, non-toxic amount of a non-radioactive contrast agent in particulate or colloidal form for use in performing percutaneous lymphography, wherein the mean size of the particles is from 5 to 900 manometers in diameter, and where said contrast agent is capable of localizing in the lymph nodes of a mammal to allow the imaging of lymph nodes in which said contrast agent has localized with sufficient resolution to permit visualization of intranodal architecture.
2. A composition according to Claim 1, wherein at least 80% (by volume) of said particles are between 10 and 500 manometers in diameter.
3. A composition as claimed in Claim 1, wherein at least 20% (by volume) of the particles are 200 manometers in diameter or less.
4. A composition as claimed in any of Claims 1 to 3, wherein the particles are superparamagnetic or ferromagnetic, or comprise an insoluble metal colloid, a lipid-soluble iodinated compound or an imageable fluorocarbon.
5. A composition as claimed in Claim 4, wherein the contrast agent is a brominated perfluorocarbon.
6. A composition as claimed in Claim 5, wherein the contrast agent is perfluorooctylbromide.
7. A composition as claimed in Claim 4, wherein the contrast agent is a mono-, di-, or tri-iodinated perfluorocarbon.
8. A composition as claimed in any of Claims 1 to 7, wherein the mean size of the particles is less than 300 nm.
9. A composition according to Claim 1, wherein the particles comprise an imageable moiety and an appropriately sized particulate carrier incorporating the imageable moiety.
10. Use of a composition according to any one of Claims 1 to 9 in performing percutaneous lymphography, wherein said contrast agent is adapted to localize in the lymph nodes of a mammal following interstitial administration to allow the imaging of the intranodal architecture of the lymph node in which the contrast agent has localized.
11. Use of a composition according to any one of Claims 1 to 9 to image the intranodal architecture of lymph nodes, wherein the imaging is performed by MRI, ultrasound, X-ray, a digital subtraction technique or by computed tomography.
12. Use of a composition according to any one of Claims 1 to 9 where the contrast agent is adapted to localize in lymph nodes afferent to a site where the composition has been interstitially administered, wherein said site comprises hand, foot, or limb, in order to allow the imaging of axillary, popliteal, or lingual nodes.
13. A process for the preparation of a fluorocarbcn contrast medium suitable for interstitial administration, comprising the steps of:
forming an aqueous emulsion having a continuous aqueous phase and having a dispersed fluorocarbon liquid phase having a mean particle size between about 5 and about 900 nanometers and having the ability to localize in lymph nodes after interstitial administration into the tissue of a mammal and being imagable with sufficient resolution to permit visualization of intranodal architecture; and removing at least some of the aqueous phase to concentrate the emulsion.
14. A process as claimed in Claim 13, wherein the fluorocarbon phase has a mean particle size less than 150 nanometers.
15. A process as claimed in Claim 13, wherein said concentrating step comprises dialysis, ultrafiltration, or reverse osmosis.
16. A process as claimed in Claim 13, wherein at least 20 volume percent of said fluorocarbon phase has a particle size less than 300 nanometers.
17. Use of a non-radioactive imageable particulate material having a mean particle size between 5 nanometers and 900 nanometers in the preparation of a diagnostic composition for use as a contrast agent for interstitial administration to a mammal to visualize intranodal architecture of lymph nodes through indirect lymphography.
18. Use of the imageable particulate material in the preparation of a diagnostic composition for use as a contrast agent as claimed in Claim 17, wherein said imageable particulate material comprises the composition as claimed in any one of claims 1 to 9.
19. A composition as claimed in any one of Claims 1 to 9 in the form of a pharmaceutical composition for use as a contrast agent for interstitial administration in a mammal for indirect lymphography, characterized by:
a composition comprising an imageable non-radioactive contrast agent in particulate or colloidal form having a mean particle size between 5 nanometers and 900 nanometers, in a pharmaceutically acceptable carrier suitable for injection, and adapted to localize in lymphatic system tissue after interstitial administration of said composition to a mammal.
20. The composition of Claim 19, further comprising packaging material associated with said particulate material carrying indicia reflective of governmental approval for interstitial administration of said particulate material as a contrast agent for indirect lymphography.
21. A method for performing indirect lymphography, comprising the steps of:
interstitially administering a composition comprising a diagnostically effective amount of a non-radioactive contrast agent in particulate or colloidal form to a mammal, said agent having a mean particle size from about 5 to about 900 manometers in diameter and being imageable with sufficient resolution to permit visualization of intranodal architecture;
permitting the contrast agent to localize in lymphatic system tissue afferent to the injection site;
and imaging the lymphatic system tissue in which said contrast agent has localized within about 1 month of said administration.
22. A method as claimed in Claim 21, wherein said composition is as claimed in any of Claims 1 to 9.
CA002055594A 1989-05-30 1990-05-30 Percutaneous lymphography Expired - Fee Related CA2055594C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35867889A 1989-05-30 1989-05-30
US358,678 1989-05-30
US530,034 1990-05-29
US07/530,034 US5114703A (en) 1989-05-30 1990-05-29 Percutaneous lymphography using particulate fluorocarbon emulsions
PCT/US1990/002984 WO1990014846A1 (en) 1989-05-30 1990-05-30 Percutaneous lymphography

Publications (2)

Publication Number Publication Date
CA2055594A1 CA2055594A1 (en) 1990-12-01
CA2055594C true CA2055594C (en) 2001-11-20

Family

ID=27000159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002055594A Expired - Fee Related CA2055594C (en) 1989-05-30 1990-05-30 Percutaneous lymphography

Country Status (10)

Country Link
US (2) US5114703A (en)
EP (1) EP0474785B1 (en)
JP (1) JP2865172B2 (en)
AT (1) ATE162083T1 (en)
AU (1) AU639466B2 (en)
CA (1) CA2055594C (en)
DE (1) DE69031946T2 (en)
DK (1) DK0474785T3 (en)
ES (1) ES2112836T3 (en)
WO (1) WO1990014846A1 (en)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
GB8916781D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
JP2921984B2 (en) * 1991-01-19 1999-07-19 名糖産業株式会社 Composition containing ultrafine magnetic metal oxide particles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
US5447635A (en) * 1991-02-26 1995-09-05 Bracco International B.V. Process of concentration and purification of organic compounds
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5496535A (en) * 1991-04-12 1996-03-05 Alliance Pharmaceutical Corp. Fluorocarbon contrast media for use with MRI and radiographic imaging
MX9205298A (en) * 1991-09-17 1993-05-01 Steven Carl Quay GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
EP0605477B2 (en) * 1991-09-17 2007-06-20 GE Healthcare AS Gaseous ultrasound contrast media
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
US5403575A (en) * 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
US5324503A (en) * 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
WO1994002068A1 (en) * 1992-07-21 1994-02-03 The General Hospital Corporation System of drug delivery to the lymphatic tissues
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5420359A (en) * 1992-12-11 1995-05-30 Minnesota Mining And Manufacturing Company Chlorofluoroether compositions and preparation thereof
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
SG52198A1 (en) * 1993-01-25 1998-09-28 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
FR2700696B1 (en) * 1993-01-28 1995-04-07 Atta Dispersions, emulsions, microemulsions, gels and compositions for biomedical use comprising an iodinated fluorinated organic compound, usable in particular as a contrast agent.
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
AU6365894A (en) * 1993-03-16 1994-10-11 Alliance Pharmaceutical Corporation Fluorocarbon compositions containing a visible or fluorescent label
US5492648A (en) * 1993-07-02 1996-02-20 Lau; John R. Organic oil stabilization techniques
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5851510A (en) * 1994-05-16 1998-12-22 The Board Of Regents Of The University Of Michigan Hepatocyte-selective oil-in-water emulsion
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
DE69534233T2 (en) * 1994-09-16 2005-10-27 Ethicon Endo-Surgery, Inc., Cincinnati DEVICES FOR DETERMINING AND MARKING TISSUE
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6821506B2 (en) * 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6548046B1 (en) * 1995-06-08 2003-04-15 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
DE19529922A1 (en) * 1995-08-01 1997-02-06 Schering Ag Use of liposomal preparations in indirect MRI lymphography
US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
ES2239349T3 (en) 1996-01-10 2005-09-16 Amersham Health As CONTRAST MEDIUM.
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
DE19603033A1 (en) * 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
DK0904113T3 (en) * 1996-03-05 2004-08-30 Acusphere Inc Microencapsulated fluorinated gases for use as imaging agents
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6103270A (en) * 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
CA2263568C (en) 1996-09-11 2008-12-02 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a contrast agent and a renal vasodilator
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
EP1023050B1 (en) * 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6607829B1 (en) 1997-11-13 2003-08-19 Massachusetts Institute Of Technology Tellurium-containing nanocrystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6371904B1 (en) * 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US9669113B1 (en) 1998-12-24 2017-06-06 Devicor Medical Products, Inc. Device and method for safe location and marking of a biopsy cavity
US6356782B1 (en) * 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6444192B1 (en) 1999-02-05 2002-09-03 The Regents Of The University Of California Diagnostic imaging of lymph structures
EP1202671A4 (en) 1999-08-13 2004-11-10 Point Biomedical Corp Microparticles useful as ultrasonic contrast agents and for lymphatic system
US7220401B2 (en) * 1999-09-24 2007-05-22 Barnes-Jewish Hospital Blood clot-targeted nanoparticles
WO2001058458A1 (en) * 2000-02-08 2001-08-16 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
IL157576A0 (en) * 2001-03-08 2004-03-28 Nanosolutions Gmbh Paramagnetic nanoparticle
WO2002087629A1 (en) * 2001-04-26 2002-11-07 Analogic Corporation Ct scanner for imaging a preselected portion of a patient
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP2005519657A (en) * 2001-11-07 2005-07-07 インコール ファーマシューティカル カンパニー Method of blood vessel imaging using nanoparticulate contrast agent
CA2474386C (en) 2002-01-24 2011-07-05 Barnes-Jewish Hospital Integrin targeted imaging agents
DE60309300T3 (en) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. NANOPARTICLE COMPOSITIONS OF ANGIOGENIC INHIBITORS
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
NO20024755D0 (en) 2002-10-03 2002-10-03 Amersham Health As Method
EP1419787A1 (en) * 2002-11-18 2004-05-19 Uwe Prof. Dr. Till Contrast agent for the identification of lymph nodes
AU2003297099A1 (en) * 2002-12-12 2004-06-30 Manoa Medical, Inc. Percutaneous removal of sentinel lymph node using contrast imaging for identification
US7181266B2 (en) * 2003-03-04 2007-02-20 Massachusetts Institute Of Technology Materials and methods for near-infrared and infrared lymph node mapping
JP2004269439A (en) * 2003-03-10 2004-09-30 Motohiro Takeda Agent for detecting sentinel lymph node and method for detecting the same
EP1687034A1 (en) * 2003-11-17 2006-08-09 Philips Intellectual Property & Standards GmbH Contrast agent for medical imaging techniques and usage thereof
EP2319544A1 (en) 2004-01-16 2011-05-11 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CA2569461A1 (en) 2004-06-09 2005-12-29 Kereos, Inc. Lipophilic derivatives of chelate monoamides
US20070098642A1 (en) * 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
US8263043B2 (en) * 2006-04-14 2012-09-11 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
WO2008054509A2 (en) * 2006-04-14 2008-05-08 Celsense, Inc. Methods for assessing cell labeling
AU2007244705A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
EP2053968A4 (en) * 2006-08-17 2015-10-21 Epix Pharm Inc Methods for lymph system imaging
DE102006049821A1 (en) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft New, well tolerated metal chelates, for use as radiodiagnostic, radiotherapeutic or NMR and X-ray diagnostic agents, contain chelator and perfluorinated polyethylene glycol residues
DE102007015598A1 (en) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Use of fluorochemical compounds for diagnostic purposes using imaging techniques
WO2009009105A2 (en) * 2007-07-10 2009-01-15 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
US9446150B2 (en) 2007-10-09 2016-09-20 Washington University Particles for imaging
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
CA2723171C (en) * 2008-05-02 2018-03-27 Celsense, Inc. Emulsion compositions and methods for nuclear magnetic resonance and other imaging
US8262160B2 (en) * 2008-11-14 2012-09-11 Mehri Mafi Adjustable padded chair
EA201791383A1 (en) 2009-05-27 2018-06-29 Селекта Байосайенсиз, Инк. NANOSEELS HAVE COMPONENTS WITH DIFFERENT RELEASE RATES
AU2010339809B2 (en) 2009-12-17 2016-05-05 The Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
JP2013527157A (en) 2010-04-15 2013-06-27 ワシントン・ユニバーシティ Prodrug composition, prodrug nanoparticles and methods of use thereof
NO2575876T3 (en) 2010-05-26 2018-05-05
EP2736537A4 (en) 2011-07-29 2015-04-15 Selecta Biosciences Inc Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
FR2980365B1 (en) 2011-09-26 2016-02-12 Guerbet Sa NANOEMULSIONS, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS A CONTRAST AGENT.
FR2980364B1 (en) 2011-09-26 2018-08-31 Guerbet NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS
WO2013116691A1 (en) 2012-02-02 2013-08-08 The Washington University Methods for improving muscle strength
EP3013942A4 (en) * 2013-06-24 2016-11-23 Anthrogenesis Corp Methods of expanding t cells
CA2962768C (en) * 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
KR102618877B1 (en) 2014-12-31 2023-12-28 랜티우스 메디컬 이메징, 인크. Lipid-encapsulated gas microsphere compositions and related methods
US10213448B2 (en) 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
IL262647B2 (en) 2016-05-04 2023-03-01 Lantheus Medical Imaging Inc Methods and devices for preparation of ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
CN111514317B (en) * 2020-04-09 2022-08-19 温州医科大学附属第一医院 Lymphatic system bimodal imaging contrast agent

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975512A (en) * 1970-12-21 1976-08-17 University Of Illinois Foundation Non-toxic brominated perfluorocarbons radiopaque agents
US3818229A (en) * 1970-12-21 1974-06-18 Univ Illinois Radiopaque agents comprising brominated perfluorocarbons
US4073879A (en) * 1974-08-26 1978-02-14 University Of Illinois Foundation Brominated perfluorocarbon radiopaque agents
CH615344A5 (en) * 1975-06-16 1980-01-31 Bracco Ind Chimica Spa X-ray contrast medium and process for its preparation
US4225725A (en) * 1975-10-20 1980-09-30 Mallinckrodt, Inc. Lower alkoxymethyl esters of 2,4,6-triiodobenzoic acid derivatives
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4146499A (en) * 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
DE2926428A1 (en) * 1979-06-28 1981-01-08 Schering Ag Bis:amide(s) of tri:iodo-5-amino-isophthalamide cpds. - useful as X=ray contrast agents, esp. for lymphography (PT 12.12.80)
DK273280A (en) * 1979-06-28 1980-12-29 Schering Ag TRIODED 5-AMINOISOPHTHALIC ACID DERIVATIVES
SU1061821A1 (en) * 1979-12-29 1983-12-23 Ордена Трудового Красного Знамени Институт Тепло-И Массообмена Им.А.В.Лыкова Radiopaque agent
US4404182A (en) * 1980-01-08 1983-09-13 The United States Of America As Represented By The Department Of Health And Human Services Ethiodized oil emulsion for intravenous hepatography
US4451251A (en) * 1982-03-03 1984-05-29 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4397870A (en) * 1982-07-27 1983-08-09 The University Of Pennsylvania Process for prolonging retention of emulsion particles in the bloodstream
JPS59166626A (en) * 1983-03-09 1984-09-20 Kobe Steel Ltd Continuous spheroidizing heat treatment of rod steel
CA1257828A (en) * 1984-04-16 1989-07-25 William Mccormick Perfluoro compound dispersions containing reduced amounts of surfactant and process of preparation
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
SE8505048L (en) * 1985-10-25 1987-04-26 Nutritional Int Res Inst NUTRITION EMULSION WITH ACID TRANSPORTING PROPERTIES
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
DE3785054T2 (en) * 1986-01-24 1993-07-08 Childrens Hosp Medical Center STABLE EMULSIONS OF STRONGLY FLUORED ORGANIC COMPOUNDS.
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5055288A (en) * 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
DE3709851A1 (en) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te NMR DIAGNOSTIC LIQUID COMPOSITIONS
GB8813144D0 (en) * 1988-06-03 1988-07-06 Nycomed As Compositions
GB8916781D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
JPH0946230A (en) * 1995-07-27 1997-02-14 Yamaha Corp D/a converter
JP3596953B2 (en) * 1995-08-30 2004-12-02 ポーラ化成工業株式会社 Whitening cosmetics
EP1044917B1 (en) * 1999-04-14 2003-09-10 Schärer Schweiter Mettler AG Device for winding a thread on a spool

Also Published As

Publication number Publication date
CA2055594A1 (en) 1990-12-01
JP2865172B2 (en) 1999-03-08
ES2112836T3 (en) 1998-04-16
US5114703A (en) 1992-05-19
EP0474785A1 (en) 1992-03-18
DE69031946T2 (en) 1998-09-10
US5496536A (en) 1996-03-05
WO1990014846A1 (en) 1990-12-13
DK0474785T3 (en) 1998-09-14
EP0474785B1 (en) 1998-01-14
EP0474785A4 (en) 1992-11-04
ATE162083T1 (en) 1998-01-15
AU639466B2 (en) 1993-07-29
AU5922290A (en) 1991-01-07
JPH04506078A (en) 1992-10-22
DE69031946D1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
CA2055594C (en) Percutaneous lymphography
Lusic et al. X-ray-computed tomography contrast agents
Okuhata Delivery of diagnostic agents for magnetic resonance imaging
Weissleder et al. MR lymphography: study of a high-efficiency lymphotrophic agent.
US6203778B1 (en) Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
Gabizon et al. An improved method for in vivo tracing and imaging of liposomes using a gallium 67-deferoxamine complex
US20090317327A1 (en) Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy
JP2001524096A (en) Embolic treatment using insoluble microparticles or vesicles containing contrast agents
Harika et al. Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies.
EP0442962A1 (en) Liposomal radiologic contrast agents.
Tilcock Imaging tools: liposomal agents for nuclear medicine, computed tomography, magnetic resonance, and ultrasound
WO1998044910A1 (en) NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO)
US6001333A (en) Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging
WO2005067982A2 (en) Methods for imaging the lymphatic system using dendrimer-based contrast agents
Bulte et al. Initial assessment of magnetoferritin biokinetics and proton relaxation enhancement in rats
Reimer et al. Experimental hepatocellular carcinoma: MR receptor imaging.
Davis et al. Colloidal particles as radiodiagnostic agents
Torchilin et al. In vivo visualizing of organs and tissues with liposomes
Torres et al. Gd (III)‐EPTPAC16, a new self‐assembling potential liver MRI contrast agent: in vitro characterization and in vivo animal imaging studies
JPH10120597A (en) Highly accumulating colloidal particle of lymph node
Gazelle et al. Hepatic imaging with iodinated nanoparticles: a comparison with iohexol in rabbits
JPH10513466A (en) Liposomes containing contrast agents for visualizing intravascular space
Gazelle et al. Nanocrystalline computed tomography contrast agents for blood-pool and liver-spleen imaging
FISCHER Particles
Desser et al. Interstitial MR and CT Lymphography with Gd-DTPA-co-α, ω-diaminoPEG (1450) and Gd-DTPA-co-1, 6-diaminohexane polymers: preliminary experience

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed